| MRCK34 Stock | | | BRL 77.23 1.09 1.43% |
Chairman
Mr. Kenneth C. Frazier is Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company and Merck Sharp Dohme Corporationration . Mr. Frazier also served as Executive Vice President and General Counsel of Merck Sharp Dohme Corporationration . Director, Exxon Mobil Corporation since 2009 and Pharmaceutical Research and Manufacturers of America since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association. Mr. Frazier has broad managerial and operational expertise and deep institutional knowledge, as well as a track record of achievement, integrity and sound judgment demonstrated prior to, and during his long tenure with Merck. In addition, his role as the Chair of the Board Affairs Committee of Exxon Mobil Corporation has provided him with important experience on governance issues facing public companies. since 2011.
| Age | 67 |
| Tenure | 13 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Frazier also served as Executive Vice President and General Counsel of Merck Sharp & Dohme Corporation . Director, Exxon Mobil Corporationration since 2009 and Pharmaceutical Research and Manufacturers of America since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA; Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association.
Merck Management Efficiency
The company has return on total asset
(ROA) of
0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
Merck Co has accumulated 30.69
B in total debt with debt to equity ratio
(D/E) of 97.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Merck has a current ratio of 1.34, which is within standard range for the sector. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.
It operates through four segments Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. MERCK DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 69000 people. Merck Co (MRCK34) is traded on Sao Paulo Exchange in Brazil and employs 44 people.
Management Performance
Merck Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cristal Downing, Ex Officer | |
| Jennifer Zachary, General Counsel | |
| David Williams, Ex Officer | |
| Caroline Litchfield, Ex CFO | |
| Lisa LeCointeCephas, VP Officer | |
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | |
| Kenneth Frazier, Chairman, CEO and Pres | |
| Peter Dannenbaum, VP Relations | |
| Jennifer Mauer, VP Communications | |
| Robert JD, CEO Chairman | |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Merck Stock
Merck financial ratios help investors to determine whether Merck Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Merck with respect to the benefits of owning Merck security.